Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:CDTX

Cidara Therapeutics - CDTX Stock Forecast, Price & News

$0.71
+0.02 (+2.90%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.69
$0.74
50-Day Range
$0.53
$0.77
52-Week Range
$0.40
$1.71
Volume
354,469 shs
Average Volume
346,747 shs
Market Capitalization
$50.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Cidara Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
745.1% Upside
$6.00 Price Target
Short Interest
Healthy
1.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.11mentions of Cidara Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$35,625 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.29) to $0.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

328th out of 1,040 stocks

Biological Products, Except Diagnostic Industry

50th out of 175 stocks

CDTX stock logo

About Cidara Therapeutics (NASDAQ:CDTX) Stock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Stock News Headlines

Cidara Therapeutics Could Soar On Rezafungin Approval
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
H.C. Wainwright Reaffirms Their Buy Rating on Cidara Therapeutics (CDTX)
Cidara Therapeutics Inc
See More Headlines
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/06/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+745.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-42,470,000.00
Pretax Margin
-54.21%

Debt

Sales & Book Value

Annual Sales
$49.57 million
Book Value
$0.32 per share

Miscellaneous

Free Float
66,762,000
Market Cap
$50.85 million
Optionable
Optionable
Beta
1.43

Key Executives

  • Dr. Jeffrey L. Stein Ph.D. (Age 67)
    Pres, CEO & Exec. Director
    Comp: $836.4k
  • Dr. Taylor Sandison (Age 50)
    Chief Medical Officer
    Comp: $597.9k
  • Dr. Les Tari Ph.D.
    Chief Scientific Officer
  • Dr. Kevin M. Forrest Ph.D. (Age 45)
    Founder and Chief Strategy Officer
  • Dr. Preetam Shah M.B.A. (Age 49)
    Ph.D., CFO, Chief Bus. Officer & Principal Accounting Officer
  • Mr. Shane M. Ward (Age 47)
    COO & Chief Legal Officer
  • Ms. Allison Lewis CCP
    SPHR, VP of HR
  • Mr. James M. Balkovec
    Sr. VP of Research
  • Ms. Laura A. Navalta
    Sr. VP of Clinical Operations
  • Ms. Carol Waldo
    Sr. VP of Regulatory Affairs & Quality Assurance













CDTX Stock - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings
or view top-rated stocks.

What is Cidara Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price targets for Cidara Therapeutics' stock. Their CDTX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 745.1% from the stock's current price.
View analysts price targets for CDTX
or view top-rated stocks among Wall Street analysts.

How have CDTX shares performed in 2022?

Cidara Therapeutics' stock was trading at $1.27 on January 1st, 2022. Since then, CDTX shares have decreased by 44.1% and is now trading at $0.71.
View the best growth stocks for 2022 here
.

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 724,300 shares, an increase of 45.6% from the October 31st total of 497,400 shares. Based on an average daily volume of 241,100 shares, the short-interest ratio is currently 3.0 days.
View Cidara Therapeutics' Short Interest
.

When is Cidara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our CDTX earnings forecast
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.01. The biotechnology company earned $7.08 million during the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 480.89% and a negative net margin of 54.21%.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (6.37%), Point72 Asset Management L.P. (5.40%), Renaissance Technologies LLC (1.81%), Monashee Investment Management LLC (0.53%), State Street Corp (0.32%) and BlackRock Inc. (0.27%). Insiders that own company stock include Brady Johnson, James E Levine, Jeffrey Stein, Jessica Oien, Leslie Tari, Neil Abdollahian, Paul Daruwala, Preetam Shah, Taylor Sandison and Timothy R Franson.
View institutional ownership trends
.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $0.71.

How much money does Cidara Therapeutics make?

Cidara Therapeutics (NASDAQ:CDTX) has a market capitalization of $50.85 million and generates $49.57 million in revenue each year. The biotechnology company earns $-42,470,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The official website for the company is www.cidara.com. The biotechnology company can be reached via phone at (858) 752-6170 or via email at britchie@lifesciadvisors.com.

This page (NASDAQ:CDTX) was last updated on 11/28/2022 by MarketBeat.com Staff